Tumour biology and pathology

34P - Recommendations for EGFR mutation testing with a fast and fully automated sample-to-result system: How to optimize DNA input instead of using lung cancer tissue?

Authors
  • Caroline Chapusot (FR)
Presenter
  • Caroline Chapusot (FR)

Abstract

Background

EGFR mutation detection on non-small cell lung carcinoma (NSCLC) is mandatory for optimal care of metastatic patients. Rearrangement/amplification of ALK or ROS, PDL1 expression level, BRAF, HER2 mutational status is also required. These different tests are time and tissue consuming. Therefore, molecular diagnostic laboratories need to elaborate strategies in order to optimize the realization of these different tests from limited biopsy specimens. The Idylla™ EGFR Mutation Test provided by Biocartis® is a fully automated sample–to–result test based on real-time PCR. The test allows the detection of 51 EGFR mutations directly from slices of FFPE tissue samples in less than three hours with an overall agreement of 96% with pyrosequencing. Nevertheless, further molecular tests need DNA and further tissue processing. In this project, the feasibility of EGFR testing from extracted DNA of NSCLC samples using Idylla™ EGFR was evaluated.

Methods

EGFR mutational status was evaluated with the Idylla™ EGFR cartridge in two independent series of 20 retrospective and 83 prospective cases using DNA samples extracted from NSCLC instead of tissue sections.

Results

Tumoral cellularity, DNA quantity and quality evaluated with a Tapestation Agilent® were taken into account in addition to the WT DNA CQ value calculated by the Idylla™ Explore software to optimize the DNA input. EGFR mutational status of the 20 retrospective cases previously analyzed with pyrosequencing was assessed in order to check the agreement of the fully automated method. A prospective series of 83 samples was then analyzed. All the results were interpreted and validated with the use of the Idylla™ test specific software, and qPCR curves were visualized by the Idylla™ Explore software.

Conclusions

These results suggest some recommendations to use already extracted DNA with a fully automated sample–to–result system taking into account preanalytics and analytics features to safely characterize EGFR mutational status on lung cancer samples.

Legal entity responsible for the study

University Hospital of Dijon

Funding

Biocartis company

Disclosure

All authors have declared no conflicts of interest.

Collapse

Previous ePoster
33P - Expression of biomarkers IDH1, CEA, TPA and CYFRA21-1 in peripheral blood and tissue of non-small cell lung carcinoma patients detected by real-time PCR

Next ePosters
35PD - Magnitude of exposure to biomass fuel smoke and risk of lung cancer in women: Cases and controls study
37P - Epidemiology and management of bronchopulmonary carcinoma in eastern Morocco of 738 cases
38P - Survival of lung cancer: Bangladesh perspective
40P - Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status
42P - Is there a delay in diagnosis of lung cancer in women?
No ePoster preview available
51PD - Effect of MEK inhibition on PDL1 and and on cytokinesproduction profilein NSCLC cell lines and in human lymphocites
53P - Lung cancer: Beyond EGFR and ALK dichotomy
54P - Epidermal growth factor receptor expression (EGFR) in serum as a marker of treatment response and survival in advanced squamous cell lung cancer
57P - Targeted sequencing of plasma-derived cfDNA in patients with metastatic NSCLC
58P - Co-treatment of trametinib (MEK inhibitor) with TPX-0005 (Src/FAK/JAK2 inhibitor) synergistic in KRAS mutant NSCLC cell lines and CDCP1 acts as a biomarker in KRAS mutant patients (p)